Stocklytics score rationale: value 38, quality 33, growth 12.
Financials
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
770000
16000
0
244000
5479000
12415000
17653047
25375000
43258000
559000
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of…
Forecast
Consensus Buy from 11 analysts. Average price target $20.00, +1.3% versus the current price. Low $20.00. High $20.00.
Analysts have an average 12-month price target of $20.00 for Silence Therapeutics (SLN), 1.3% above the current price of $19.73. Of 11 analysts covering the stock, 6 rate it Buy or Strong Buy, 4 Hold, and 1 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
SLN price target
12-month price target
Low
$20.00
Average
$20.00
High
$20.00
The average is 1.3% above the current price of $19.73.
Is Silence Therapeutics a buy or sell?
Of 11 analysts, 6 rate Silence Therapeutics Buy or Strong Buy, 4 Hold, and 1 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Silence Therapeutics earnings and revenue forecast
The Stocklytics Score for SLN is 28 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
SLN forecast FAQs
What is the SLN price target?
$20.00 average, with a published range of $20.00 to $20.00.
Is Silence Therapeutics a buy or sell?
The consensus is Buy from 11 analysts. This is not a recommendation.
What is the Silence Therapeutics stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -0.36. The average revenue estimate is $438,143.
What will SLN be worth in 2030?
No reliable forecast exists that far out.
When is Silence Therapeutics's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.